130 Companies to Present at Techvest's 4th Annual Healthcare Conference; August 15 early registration deadline.

Business Editors/Biotechnology, Health & Medical Writers

NEW YORK--(BUSINESS WIRE)--July 22, 2002

Techvest, LLC today announced that August 15 will be the last date to receive an early registration discount for its 4th Annual Healthcare Conference & Expo, to be held at the Boston Marriott Long Wharf Hotel on October 22-24, 2002.

The event is intended for: institutional investors, venture capitalists, accredited investors, senior corporate executives and academic investigators interested in the field. For registration and more information visit http://www.techvestllc.com/conference2001/

Institutional investors and venture capitalists should contact Manju Basavaraju at 212-262-4646 ext. 303 for free registration or can register on-line at: http://www.techvestllc.com/conference2002/

The conference will consist of two programs:

-- The Annual Conference on Tissue Repair, Replacement and Regeneration (TM), October 23-24, will feature 80 companies in the fields of tissue-engineering, cell therapy, biomaterials, gene therapy, growth factors, and transplantation.

-- The Emerging Healthcare Forum (TM), October 22-23, will feature 50 biotechnology, specialty pharmaceutical, and medical device companies. This unique program will be organized into themed tracks offering comprehensive coverage of multiple topics.

The conference also includes an Expo where companies will highlight their products, services and partnering opportunities.

Companies expected to present at this year's Techvest Healthcare Conference include:

Aastrom BioSciences, Inc. (NASDAQ:ASTM), ActivBiotics, Inc., Aderis Pharmaceuticals, Inc., Advanced Materials Design, LLC, Advanced Tissue Sciences (NASDAQ:ATIS), Aeterna Laboratories, Inc. (NASDAQ:AELA), Allos Therapeutics, Inc. (NASDAQ:ALTH), AltaRex Corporation (TSE:AXO.TO), Anika Therapeutics, Inc. (NASDAQ:ANIK), AnVil, Avanir Pharmaceuticals (AMEX:AVN), Befutur Biotechnologies, Biocompatibles International, PLC (LSE:BII.L), BioHeart, Inc., BioMimetic Pharmaceuticals, Inc., BioSyntech, Inc. (NASDAQ:BSYI), BioTissue Technologies, Inc. (FRA:BTS), BioTransplant, Inc. (NASDAQ:BTRN), BREONICS, Inc., Cell Pathways, Inc. (NASDAQ:CLPA), CellExSys, Inc., Subsidiary of Targeted Genetics (NASDAQ:TGEN), CellFactors, PLC, Chrysalis BioTechnology, Closure Medical Corporation (NASDAQ:CLSR), co.don AG (XETRA:CNWG.DE), Colbar R&D, LTD, Coley Pharmaceutical Group, Inc., Crucell NV (NASDAQ:CRXL), Curis (NASDAQ:CRIS), Cytochroma, Inc., Dendreon Corporation (NASDAQ:DNDN), Dentigenix, Devlogen AG, diaDexus, Inc., Discovery Labratories, Inc. (NASDAQ:DSCO), DURECT Corporation (NASDAQ:DRRX), Dynavax Technologies Corporation, EpiCept Corporation, ES Cell International, PTE, LTD, FibroGen, Inc., Fidia Advanced Biopolymers, S.R.L., Flamel Technologies S.A. (NASDAQ:FLML), GENETIX Pharmaceuticals, Inc., Genicon Sciences Corporation, Genzyme BioSurgery (NASDAQ:GZBX), GlycoGenesys, Inc. (NASDAQ:GLGS), Guilford Pharmaceuticals, Inc. (NASDAQ:GLFD), HK Pharmaceuticals, Inc., Hybridon, Inc. (NSADQ:HYBN), ImmunoGen, Inc. (NASDAQ:IMGN), Incara Pharmaceuticals (NASDAQ:INCR), Integra Life Sciences Holdings Corporation (NASDAQ:IART), InterCure, Inc., Interface Biologics, Islet Technology, Inc., IsoTis NV (AMS:ISOT.AS), Isto Technologies, Kensey Nash Corporation (NASDAQ:KNSY), Kourion Therapeutics AG, LifeCell Corporation (NASDAQ:LIFC), Lorantis, LTD, MacroGenics, Inc., MacroPore BioSurgery (Neuer Markt:XMP), MaxCyte, Inc., MicroIslet, Inc. (NASDAQ:MIIS), Micromet AG, Mojave Therapeutics, Inc., Musculoskeletal Transplant Foundation (not-for-profit), Nastech Pharmaceutical Company (NASDAQ:NSTK), Neuralstem, Inc., NeuroNova AB, NewBiotics, Inc., Norak BioSciences, Inc., NOXXON Pharma, A.G., Oncolytics Biotech, Inc. (NASDAQ:ONCY), Onyx Pharmaceuticals (NASDAQ:ONXX), OraPharma, Inc. (NASDAQ:OPHM), Organ Recovery Systems, Inc., Orthologic Corporation (NASDAQ:OLGC), Osteotech, Inc. (NASDAQ:OSTE), Oxigene, Inc. (NASDAQ:OXGN), Pharmacopeia, Inc. (NSADQ:PCOP), Proneuron Biotechnologies, Questcor Pharmaceuticals, Inc. (AMEX:QSC), Quorex Pharmaceuticals, Inc., Regen Biologics, Regeneration Technologies, Inc. (NASDAQ:RTIX), RegeneRX Biopharmaceuticals, Inc. (OTCBB:RGRX), Selective Genetics, Serenex, Inc., Sertoli Technologies, Inc., Spectranetics Corporation (NASDAQ:SPNC), Synaptica Limited, Targeted Genetics Corporation (NASDAQ:TGEN), Tissue Transformation Technologies, TolerRX, Inc., Transition Therapeutics, Inc. (CDNX:TTH.V), Verigen AG, Xenova Group plc (NSADAQ:XNVA), Ximerex, Inc., XTL Biopharmaceuticals, LTD (LONDON:XTL.L)

If you believe that your company should present at either the Annual Conference on Tissue Repair, Replacement and Regeneration or the Emerging Healthcare Forum, or exhibit at the Expo, please contact Michael Ehrenreich at 212-262-4646 ext.304 or e-mail: [e-mail].

The Techvest Annual U.S. Healthcare Conference is sponsored in part by Palmer & Dodge, LLP.

Techvest, LLC is an investment bank specializing in the healthcare sector.

http://www.techvestllc.com/conference2001/